Abstract
Background: Endometrium is capable of marked hyperplasia as a response to stimulus of prolonged and
unopposed oestrogen. The present study was conducted to assess endometrial hyperplasia in females.
Materials
& Methods: The present study was conducted on 45 females with history of menorrhagia.
General information such as name, age, drug history of estrogen etc. was recor ded. Per rectum examination
was done in all patients. In all patients, transvaginal ultrasound (TVS) was doneto seeendometrial thickness
and ovarian enlargement. After curettage, histopathology of the specimens was done.
Results
Age group 40-45 years had 22 patients, 45-50 had 14, 50-55 had 8 and 55-60 years had 6 patients.
The difference was significant (P - 0.01). Type of hyperplasia was cystic hyperplasia (28), adenomatous
hyperplasia (10) and atypical hyperplasia (7). The difference was significant (P - 0.05). Endometrial
thickness on transvaginal ultrasound (TVS) was 5 -6 mm seen in 7 cases, 7 -8 mm seen in 12 cases and >10
mm seen in 26 cases. The difference was significant (P<0.05).
Conclusion
Author concluded that endometrial hyperplasia was most commo nly seen in age group 40- 45
years. Most common type of hyperplasia was cystic hyperplasia.
Keywords
Cystic hyperplasia, endometrial hyperplasia, transvaginal ultrasound
Introduction
Endometrium is capable of marked hyperplasia as a response to stimulu s of prolonged and
unopposed oestrogen. Of the two systems used to classify EH, namely, the World Health
Organization (WHO) and the endometrial intraepithelial neoplasia (EIN) classification systems,
the EIN system is more objective than the WHO system, but the latter is more widely used [1].
Simple or cystic hyperplasia is a benign proliferation of endometrial glands that are irregular and
dilated but do not display back to back crowding or cellular atypia. Complex adenomatous
hyperplasia is a proliferatio n of endometrial glands with irregular outline architectural
complexity and back to back crowding but no atypia [2].
The endometrioid adenocarcinoma is the most frequent histologic variant, accounting for 58 -
80% of the cases. Almost all cases of that histo logic type are hormone-dependent and associated
with obesity, exogeneous use of hormones, and elevated estrogen levels. The lesion is known to
arise from an endometrial hyperplasia. The risk of progression of hyperplasia into endometrioid
carcinoma is more closely related to the presence of cytologicatypia and to architectural
crowding [3].
Epplein et al . [4] in their study of risk of complex and atypical endometrial hyperplasia in
relation to anthropometric measures and reproductive history found that estr ogen-only hormone
therapy, which is a type of menopausal hormone therapy (MHT), is a risk factor for EH.
Armstrong et al. [5] conducted a study of diagnosis and management of endometrial hyperplasia
suggested that hormonal therapy is the major risk factor in women leading to endometrial
hyperplasia. The present study was conducted to assess endometrial hyperplasia in females.
Materials
& Methods
The present study was conducted in the department of Gynecology & Obstetrics. It comprised of
45 females with hi story of menorrhagia. All were informed regarding the study and written
consent was obtained. Ethical clearance was taken before starting the study from the institutional
ethical committee.
General information such as name, age, drug history of estrogen et c. was recorded. All were
subjected to general physical and pelvic examination. Per rectum examination was done in all
patients. Routine investigations such as blood group, Rh-factor, random blood sugar and urine
International Journal of Clinical Obstetrics and Gynaecology
~ 14 ~
routine was performed. In all patients, t rans vaginal ultrasound
(TVS) was done to see for endometrial thickness and ovarian
enlargement. Curettage and histopathology of the specimens was
done. Results thus obtained were subjected to statistical analysis
using chi - square test. P value less than 0.05 was considered
significant.
Results
Table I: Age wise distribution of cases
Age group (years) Number P value
40-45 22
0.01 45-50 14
50-55 8
55-60 6
Table I shows that age group 40 -45 years had 22 patients, 45 -50
had 14, 50 -55 had 8 and 55 -60 years had 6 patients. The
difference was significant (P- 0.01).
Table II: Type of endometrial hyperplasia
Type Number P value
Cystic hyperplasia 28
0.05 Adenomatous hyperplasia 10
Atypical hyperplasia 7
Total 45
Table II shows that type of hy perplasia was cystic hyperplasia
(28), adenomatous hyperplasia (10) and atypical hyperplasia (7).
The difference was significant (P- 0.05).
Graph I: Endometrial thickness on transvaginal ultrasound (TVS)
Graph I shows that endometrial thickness on tra nsvaginal
ultrasound (TVS) was 5 -6 mm seen in 7 cases, 7 -8 mm seen in
12 cases and >10 mm seen in 26 cases. The difference was
significant (P<0.05).
Discussion
Endometrial hyperplasia is a precursor of endometrial
carcinoma. It accounts for 6% of new female cases and 3% of
female cancer deaths. It is the most common malignancy of
female reproductive tract. Studies have revealed that
oestrogentherapy, obesity, diabetes early menarche and late
menopause are amongst various risk factors for endometrial
hyperplasia. The risk of progression of hyperplasia into
endometrial carcinoma is more closely related to the presence of
cytologic atypia and to architectural crowding. The morphologic
distinction between atypical hyperplasia and well -differentiated
carcinoma i n an endometrial biopsy or in curetting may be
problematic with a marked variation of inter-observer
correlation [6].
In present study, 45 females were found to have endometrial
hyperplasia. We found that age group 40 -45 years had 22
patients, 45 -50 had 14 , 50 -55 had 8 and 55 -60 years had 6
patients. This is in agreement with Tavasoli et al. [7]
The simple cystic hyperplasia is a benign proliferation with the
reported risk 0 -1% of progression into carcinoma. In this study,
type of hyperplasia was cystic hyp erplasia (28), adenomatous
hyperplasia (10) and atypical hyperplasia (7). Amera et al. [8] in
their study found that out of 100 patients, 15patients were found
to have endometrial hyperplasia, 10 patients simple cystic
hyperplasia, 3patients had adenomotou s hyperplasia, 2 patients
had atypical hyperplasia, 8 patients had menorrhagia , 1 with
polymenorrhagia, and 6 patients with polymenorrhoea. 13
patients were treated medically, 5 patients needed surgical
treatment following medical treatment, 2 patients und erwent
total abdominal hysterectomy (TAH) and bilateral
salpingooophorectomy (BSO) who were 51 –53 years of age
with atypical hyperplasia. Author suggested that endometrial
hyperplasia is a pre -malignant condition; if treated in time,
incidence can be reduc ed and early treatment can increase life
expectancy and quality in women over age of 45 years.
Horn et al . [9] found that 86% of the patients presented with
obesity, 23% had an exogeneous use of estrogens. The leading
symptom was vaginal bleeding in 65.5% of patients. 91% had
complex, 92% had atypical hyperplasia and 89% had
endometrioidcarcinoma, representing an overall correlation of
90%. 2% of the cases with complex hyperplasia progressed into
carcinoma and 10.5% into atypical hyperplasia. 52% of the
atypicalhyperplasias progressed into carcinomas. In the case of
progestogen treatment, 61.5% showed remission confirmed by
re-curetting, compared with 20.3% of the cases without
hormonal treatment.
We subjected patients to TVS and found that endometrial
thickness was 5-6 mm seen in 7 cases, 7 -8 mm seen in 12 cases
and >10 mm seen in 26 cases. This is similar to Campbel et al.
[10] Jin [11] in her study included 1,868 women with EH and 868
women with EC. The mean ages of the patients were 44.1 - 0.4
years for th ose with EH and 52.7 - 0.6 years for those with EC.
The EH and EC incidence rates were 3.7%woman -years and 8%
woman-years, respectively. The EH and EC incidence rates
peaked when the women were in their late forties and fifties,
respectively.
In a study by Terakawa et al. [12], 51 patients with endometrial
hyperplasia were followed for 6 months, with repeated
endometrial biopsy monthly for 3 months and at the end of 6
months. In 69% histology became normal. Jalil R [13] correlated
the indications of abdominal hysterectomy with histopahological
findings in her reports preoperative diagnosis, by D&C of
endometrial hyperplasia was14.42%.
In the study of Ferenczy and Gelfand [14] it is stated that 10 out
of 20 patients treated with progestogens for ‘endometrial
hyperplasia with cytologicatypia’ had a persistence and five of
them recurred. Additionally, five patients developed an
adenocarcinoma during a mean follow uptime 5.5 years.
Progestogens are the treatment of choice of endometrial
hyperplasia because of their i nhibitory effect on epithelial
proliferation. They act by reducing estrogenic receptors and
increasing their catabolism, stimulating the 17 -b-
hydroxyesteroid dehydrogenase and sulfotransferase enzymes
and thereby diminishing the estrogenic dominant conditions that
lead to endometrial abnormalities which occur in
hyperestrogenism.
International Journal of Clinical Obstetrics and Gynaecology
~ 15 ~
Conclusion
Author concluded that endometrial hyperplasia was most
commonly seen in age group 40 - 45 years. Most common type
of hyperplasia was cystic hyperplasia.
References
1. Kurman RJ, Kamiriski PF, Norris HJ. The behavior of
endometrial hyperplasia; A long term study of untreated
endometrial hyperplasia in 170 patients. Cancer . 1985;
56:403-12.
2. Wentz WB. Progestin therapy in endometrial hyperplasia.
Gynaecol Oncol. 1974; 2:362-7.
3. Mishal DR, Droegmuller -W, Merbot -AL. Abdominal
uterine bleeding. Corhensive Gynaecology, 2011, 953-64.
4. Fayyaz S, Majeed SS. Audit of Gynaecological
hysterectomies. J Postgrad Med Inst. 2001; 15(2):208–12.
5. Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima
A, Noda K et al. The behavior of endometrial hyperplasia:
aprospective study. J Obstet Gynaecol Res . 1997;
23(3):223-30.
6. Menwissen JH et al. Endometrial Biopsy the female patient
1993; 4:19–23.
7. Tavasoli, Ben Yehuda OM, Kim YB, Leuchter RS. Does
Hysteroscopy improve upon the sensitivity of dilatation and
curettage in the diagnosis of endometrial hyperplasia or
carcinoma? Gynaecol Oncol 1998; 68(1):4-7.
8. Amera, Tan KT, Pang MW. Ho TH. Endometrial
hyperplasia and the risk of endometrial carcinoma.
Singapore Med J. 1997; 38(1):11–5.
9. Horn, Reich O, Tamussino K, Bader AA, Pieber D, Schöll
W et al. Concomitant endometrial Hyperplasia in patients
with endometrial carcinoma. Gynaecol Oncol. 1998;
69(1):64-8.
10. Campbel, Colacurci N, De Placido G, Mollo A, Perino A,
Cittadini E. Short term use of Goserlin Depot in the
treatment ofdys functional uterine bleeding. Clin Exp Obstet
Gynecol. 1995; 22:212-9.
11. Jin RJ. Not so benign endometrial hyperplasia: endometrial
cancer after endometrial ablation. J Am Assoc Gynaecol
Laprarosc. 1997; 4(4):507-11.
12. Terakawa, Kaku T, Tsukamoto N, Hachisuga T et al .
Endometrial carcinoma associated with hyperplasia.
Gynecol Oncol. 1996; 60:22-5.
13. Jalil, Skov BG, Broholm H, Engel U et al. Comparison of
there producibility of the WHO classifications of 19 75 and
1994 of endometrial hyperplasia. Int J Gynecol Pathol.
1997; 16:33-7.
14. Ferenczy and Gelfand. Endometrioidneoplasia retrogressive
terminology. AmJ Surg Pathol. 2000; 24:754-5.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.